November 17, 2016 - By Ruchi Gupta · 0 Comments
PROTEON THERAPEUTICS INC (NASDAQ:PRTO) institutional sentiment decreased to 0.36 in 2016 Q2. Its down -1.08, from 1.44 in 2016Q1. The ratio dived, as 9 investment managers started new or increased holdings, while 25 sold and decreased their positions in PROTEON THERAPEUTICS INC. The investment managers in our partner’s database now possess: 8.28 million shares, down from 8.67 million shares in 2016Q1. Also, the number of investment managers holding PROTEON THERAPEUTICS INC in their top 10 holdings was flat from 3 to 3 for the same number . Sold All: 14 Reduced: 11 Increased: 6 New Position: 3.
Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The company has a market cap of $167.79 million. The Firm is involved in research and development activities. It currently has negative earnings. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
About 53,129 shares traded hands or 47.40% up from the average. Proteon Therapeutics Inc (NASDAQ:PRTO) has risen 5.62% since April 15, 2016 and is uptrending. It has outperformed by 0.99% the S&P500.
According to Zacks Investment Research, “Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass.”
Abingworth Llp holds 17.03% of its portfolio in Proteon Therapeutics Inc for 2.02 million shares. Mpm Asset Management Llc owns 983,381 shares or 2.56% of their US portfolio. Moreover, Ra Capital Management Llc has 1.81% invested in the company for 1.63 million shares. The Delaware-based Tiverton Asset Management Llc has invested 1.19% in the stock. Deer Vii & Co. Ltd., a New York-based fund reported 315,101 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 1 insider purchase, and 0 sales for $23,110 net activity.
Ratings analysis reveals 100% of Proteon Therapeutics’s analysts are positive. Out of 6 Wall Street analysts rating Proteon Therapeutics, 6 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $18 while the high is $27. The stock’s average target of $21 is 111.06% above today’s ($9.95) share price. PRTO was included in 7 notes of analysts from November 11, 2015. On Thursday, September 22 the stock rating was initiated by H.C. Wainwright with “Buy”. The firm has “Buy” rating given on Thursday, November 10 by Maxim Group. The stock of Proteon Therapeutics Inc (NASDAQ:PRTO) has “Outperform” rating given on Wednesday, November 11 by Raymond James. Robert W. Baird initiated Proteon Therapeutics Inc (NASDAQ:PRTO) on Thursday, April 14 with “Outperform” rating. The stock of Proteon Therapeutics Inc (NASDAQ:PRTO) has “Strong Buy” rating given on Wednesday, October 26 by Raymond James. JMP Securities maintained Proteon Therapeutics Inc (NASDAQ:PRTO) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $27 price target.
Proteon Therapeutics, Inc., incorporated on March 24, 2006, is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Firm is involved in research and development activities. The Company’s product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Firm has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). It initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs.
More news for Proteon Therapeutics Inc (NASDAQ:PRTO) were recently published by: Marketwatch.com, which released: “Proteon Therapeutics upgraded to strong buy from outperform at Raymond James” on October 20, 2014. Quotes.Wsj.com‘s article titled: “News Proteon Therapeutics Inc.PRTO” and published on October 18, 2014 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta